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DEC 2 9 2017
STATE OF MAINE
KENNEBEC, ss.

OFFICE OR

SUPERIOR COURT
CIVIL ACTION
Docket No. CV-17- J l %

ATTORNEYGENERÄL

STATE OF MAINE,
Plaintiff
V.

BOEHRINGER INGELHEIM
PHARMACEUTICALS, INC.
Defendant

)
)
)
)
)
)
)
)
)
)

CONSENT JUDGMENT

Plaintiff, State of Maine, has filed a concurrent Complaint for a permanent injunction and
other relief in this matter pursuant to 5 M.R.S. § 209 of the Maine Unfair Trade Practices Act,
and Plaintiff, by its counsel, and Defendant Boehringer Ingelheim Pharmaceuticals, Inc., by its
counsel, have agreed to the entry of this Consent Judgment (the “Judgment”) by the Court
without trial or adjudication of any issue of fact or law, and without finding or admission of
wrongdoing or liability of any kind.
NOW THEREFORE, IT IS HEREBY ORDERED THAT:
1. PARTIES
1.1

Plaintiff, State of Maine, is represented by its Attorney General, Janet T Mills,

who is charged with the responsibility for enforcing the Maine Unfair Trade Practices Act, 5
M.R.S. §§ 205-A through 214,
1.2

Defendant, Boehringer Ingelheim Pharmaceuticals, Inc. (“BIPI”), is a Delaware

coiporation with its principal place of business at 900 Ridgebury Road in Ridgefield,
Connecticut. At all relevant times, BIPI did business in the State of Maine by marketing, selling,
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and Promoting the drugs Aggrenox, Atrovent, Combivent, and Micardis (the “Covered
Products”).
2. PREAMBLE
2.1

Prior to the execution of this Judgment, BIPI represents that it voluntarily

established a compliance program that is applicable to all BIPI employees.
2.2

BIPI further represents that its compliance program includes a Compliance

Officer; a Code of Conduct; written policies and procedures; education and training initiatives; a
disclosure program that allows for confidential disclosure and investigation of potential
compliance violations and appropriate disciplinary procedures; and regular internal auditing
procedures.
3. m m m G S
3.1

This Court has jurisdiction over the subject matter of this lawsuit and over all

3.2

The terms of this Judgment shall be governed by the laws of the State of Maine.

3.3

Entry of this Judgment is in the public interest and reflects a negotiated agreement

parties.

among the parties.
3.4

The parties have agreed to resolve the issues resulting from the Covered Conduct

by entering into this Judgment.
3.5

BIPI is willing to enter into this Judgment regarding the Covered Conduct in

order to resolve the Signatory Attorney GeneraTs concerns under the State Consumer Protection
Laws as to the matters addressed in this Judgment and thereby avoid significant expense,
inconvenience, and uncertainty.
3.6

BIPI is entering into this Judgment solely for the purpose of settlement, and

nothing contained herein may be taken as or construed to be an admission or concession of any
2
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violation of law, or regulation, or of any other matter of fact or law, or of any liability or
wrongdoing, including allegations in the Complaint, all of which BIPI expressly denies. BIPI
does not admit any violation of law, and does not admit any wrongdoing that was, or could have
been, alleged by the Signatory Attorney General before the date of the Judgment. No part of this
Judgment, including its statements and commitments, shall constitute evidence of any liability,
fault, or wrongdoing by BIPI.
3.7

This Judgment shall not be construed or used as a waiver or limitation of any

defense otherwise available to BIPI in any action, or of BIPI’s right to defend itself from, or
make any arguments in, any private individual, regulatory, governmental, or class claims or suits
relating to the subject matter or terms of this Judgment. Nothing in this Judgment shall waive,
release, or otherwise affect any claims, defenses, or positions BIPI may have in connection with
any investigations, claims, or other matters the State of Maine is not releasing hereunder. This
Judgment is made without trial or adjudication of any issue of fact or law or finding of liability
of any land. It is the intent of the parties that this Judgment shall not be binding or admissible in
any other matter, including, but not limited to, any investigation or litigation, other than in
connection with the enforcement of this Judgment. Unless otherwise provided under state law,
no part of this Judgment shall create a private cause of action or confer any right to any third
party for violation of any federal or state statute, except that a State may file an action to enforce
the terms of this Judgment. Notwithstanding the foregoing, the State of Maine may file an action
to enforce the terms of this Judgment.
3.8

This Judgment (or any portion thereof) shall in no way be construed to prohibit,

limit, or restrict BIPI horn making representations with respect to the Covered Products that are
permitted or authorized under federal law, the Federal Food, Drug & Cosmetic Act (the

3

{

i

“FDCA,” 21 U.S.C. § 301 et seq.), U.S. Food and Drag Administration (the “FDA”) regulations,
or FDA Guidances for Industry, currently issued or as revised. Further, the Judgment shall in no
way prohibit, limit, or restrict BIPI from making representations with respect to the Covered
Products that are required or authorized by, or consistent with the FDA-approved Labeling or
prescribing information, or by any Investigational New Drug Application, New Drug
Application, Supplemental New Drug Application, or Abbreviated New Drug Application filed
with the FDA so long as the representation, taken in its entirety, is not false, misleading or
deceptive.
3.9

Nothing in this Judgment shall require BIPI to:
(a)

take any action that is prohibited by the FDCA or any regulation promulgated
thereunder, or by the FDA; or

(b)

fail to take any action that is required by the FDCA or any regulation
promulgated thereunder, or by the FDA.
4. DEFINITIONS

The following definitions shall be used in construing this Judgment:
4.1

“BIPI” means Boehringer Ingelheim Pharmaceuticals, Inc., including all of its

past and present subsidiaries, predecessors, successors, and assigns.
4.2

“BIPI Marketing” shall mean BIPI personnel responsible for marketing Covered

Products in the United States.
4.3

“BIPI Medical” shall mean BIPI personnel who are highly trained experts with

specialized scientific or medical knowledge whose roles involve the provision of specialized
medical or scientific information, scientific analysis, and/or scientific information to HCPs, but
excludes anyone performing sales, marketing, or other commercial roles.
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4.4

“BIPI Sales” shall mean the BIPI sales force responsible for sales of Covered

Products in the United States, including, but not limited to, the field force and all management
personnel such as district managers, regional managers, vice president(s) over sales, and
president over sales.
4.5

“Clear(ly) and Conspicuous(ly)” shall mean, with respect to a disclosure or

information presented, that such information meets requirements of the FDCA, the requirements
of FDA regulations, and the recommended actions in FDA Guidances for Industry, including
FDA’s “Guidance for Industry: Presenting Risk Information in Prescription Drug and Medical
Device Promotion,” or as revised.
4.6

“Covered Conduct” shall mean BiPI’s Promotional and marketing practices, and

dissemination of information and remuneration to HCPs regarding the Covered Products through
the Effective Date of the Judgment.
4.7

“Covered Produces)” shall mean BIPPs drugs Aggrenox, Atrovent, Combivent,

and Micardis, which have all been approved by FDA.
4.8

“Effective Date” shall mean the date on which a copy of this Judgment, duly

executed by BIPI and by the Signatory Attorney General, is approved by, and becomes a
Judgment of the Court.
4.9

“FDA Guidances for Industry” shall mean documents, as currently drafted or as

revised, issued by the FDA, pursuant to 21 U.S.C. § 371(h), that represent the FDA’s current
thinking on a topic.
4.10

“HCP” shall mean any physician or other health care practitioner, who is licensed

to provide health care services or to prescribe pharmaceutical products.
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4.11

“Labeling” shall mean all labels and other written, printed, or graphic matter (a)

upon any article or any of its containers or wrappers, or (b) accompanying such article.
4.12

“Medical Information Response(s)” shall mean a non-Promotional, scientific

communication to address an Unsolicited Request for medical information from a HCP.
4.13

“Multistate Executive Committee” shall mean the Attorneys General and then-

staffs representing Arizona, the District of Columbia, Illinois, Indiana, Kansas, Nevada,
Pennsylvania, Tennessee, and Texas.
4.14

“Multistate Working Group” shall mean the Attorneys General and their staffs

representing Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware,
the District of Columbia, Florida, Georgia, Hawaii1, Idaho, Illinois, Indiana, Iowa, Kansas,
Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi,
Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York,
North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South
Carolina, South Dakota, Tennessee, Texas, Utah2, Vermont, Virginia, Washington, West
Virginia, Wisconsin, and Wyoming.
4.15

“Off-Label” shall mean a use, including indication, dosage, population, and/or

method of administration, not consistent with the use approved by the FDA in the Labeling for a
Covered Product at the time information regarding such use was communicated, or at the time
the conduct occurred.

1Hawaii is being represented on this matter by its Office of Consumer Protection, an agency which is not part o f the
state Attorney General’s Office, but which is statutorily authorized to undertake consumer protection functions,
including legal representation of the State of Hawaii. For simplicity, the entire group will be referred to as the
“Attorneys General,” and such designation, as it includes Hawaii, refers to the Executive Director o f the State of
Hawaii Office of Consumer Protection,
2 The Utah Attorney General’s Office represents the Utah Division of Consumer Protection (Division), the state
agency charged with enforcement of the Consumer Sales Practices Act, in this action, but is not a party itself. As to
Utah, the definition of “Attorneys General” means the Utah Attorney General as counsel to the Division.
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“Promotional/’ “Promoting,” or “Promote” shall mean representations made to

HCPs, patients, consumers, payors, and other customers, about a Covered Product and other
practices intended to increase sales in the United States, or that attempt to influence prescribing
practices of HCPs in the United States, including direct-to-consumer.
4.17

“Promotional Materials” shall mean any item used to Promote a Covered Product.

4.18

“Promotional Speaker(s)” shall mean a HCP speaker engaged by or on behalf of

BIPI to Promote a Covered Product in the United States.
4.19

“Reprints Containing Off-Label Information” shall mean articles or reprints from

a scientific or medical journal, as defined in 21 C.F.R. 99.3©, or reference publication, as
defined in 21 C.F.R. 99.3©, describing an Off-Label use of a Covered Product.
4.20

“Signatory Attorney General” shall mean the Attorney General of Maine or her

authorized designee, who has agreed to this Judgment.
4.21

“State Consumer Protection Laws” shall mean the Maine Unfair Trade Practices

4.22

“Unsolicited Request” shall mean a request for information communicated to an

Act.

agent of BIPI that has not been prompted by or on behalf of BIPI.
4.23

Any reference to a written document shall mean a physical paper copy of the

document, an electronic version of the document, or electronic access to such document.
5. COMPLIANCE PROVISIONS
The following Compliance Provisions, Paragraphs 5.3 through 5.24, shall apply for five
(5) years from the Effective Date of this Judgment.
Promotional Activities
5.1

BIPI shall not make, or cause to be made, any written or oral claim that is false,

misleading, or deceptive regarding any Covered Product.
7
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BIPI shall not represent that any Covered Product has any sponsorship, approval,

characteristics, ingredients, uses, benefits, quantities, or qualities that it does not have.
5.3

BIPÏ shall not promote any Covered Product for any Off-Label use.

5.4

In Promotional Materials for Covered Products, BIPI shall Clearly and

Conspicuously disclose the risks associated with the Covered Products as set forth in the
products5 Labeling and shall present information about effectiveness and risk in a balanced
manner.
5.5

BIPI shall require that all Promotional Speakers for any Covered Product comply

with BIPI’s obligations contained in this Judgment.
5.6

BIPI shall notify BIPI Sales promptly of any warning letter received from the

FDA that affects the conduct of any sales representative in Promoting the relevant Covered
Product and shall promptly disseminate a description of the concerns described in the warning
letter.
5.7

BIPI shall not Promote a Covered Product by misrepresenting any clinical

treatment guideline in a manner that suggests a Covered Product is approved for uses not
consistent with the FDA-approved prescribing information.
Product Sampling
5.8

BIPI shall provide samples of a Covered Product only to those HCPs whose

clinical practice is consistent with the product’s FDA-approved Labeling.
5.9

If a HCP whose clinical practice is inconsistent with a Covered Product’s

Labeling requests samples of that Covered Product, BIPI personnel shall refer the HCP to BIPI
Medical where the HCP can speak directly with a BIPI Medical representative who will provide
answers to the HCP’s questions about the Covered Product, and BIPI may provide him/her with
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samples only if appropriate (i.e., if the HCP requests the samples for an FDA-approved [onlabel] use).
Financial Incentives to BIPI Sales and/or BIPI Marketing
5.10

BIPI’s financial incentives shall be designed to ensure that BIPI Sales and/or BIPI

Marketing are not motivated to engage in improper Promotion, sales, and marketing of Covered
Products.
5.11

BIPI’s financial incentives shall not include mechanisms to provide incentive

compensation for sales that may indicate Off-Label use of any Covered Product.
Dissemination and Exchange of Medical Information
5.12

The content of BIPPs communications concerning Off-Label uses of a Covered

Product shall not be false, misleading, or deceptive. BIPI shall not knowingly disseminate any
Medical Information Response, including one that describes any Off-Label use of a Covered
Product, unless such information and materials comply with the standards in applicable FDA
regulations and with recommendations in FDA Guidances for Industry.
5.13

BIPI Sales and BIPI Marketing shall not develop Medical Information Responses

regarding a Covered Product.
5.14

Medical Information Responses to Unsolicited Requests for Off-Label

information regarding a Covered Product may be disseminated only by BIPI Medical, except in
circumstances implicating public health or safety issues.
5.15

BIPI Medical shall have ultimate responsibility for developing and approving all

Medical Information Responses regarding a Covered Product. Additional approvals may be
provided by BIPPs legal department. BIPI shall not distribute any such materials unless:
(a)

clinically relevant information is included in these materials to provide scientific
balance;
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(b)

data in these materials are presented in an unbiased, non-Promotional manner; and

(c)

these materials are Clearly and Conspicuously distinguishable from sales aids and
other Promotional Materials.

5.16

Nothing in this subsection shall prohibit BIPI Medical from disseminating

materials that are permitted to be distributed under Federal law, Federal regulations, or FDA
published Guidance, unless false, misleading, or deceptive.
Responses to Unsolicited Requests for Off-Label Information
5.17

If BIPI elects to respond to an Unsolicited Request for Off-Label information

regarding a Covered Product, BIPI Medical shall provide specific, accurate, objective, and
scientifically balanced responses. Any such response shall not Promote a Covered Product for
any Off-Label use.
5.18

Any written BIPI response to an Unsolicited Request for Off-Label information

regarding a Covered Product shall be a Medical Information Response and shall include:
(a)

a copy of the FDA-required Labeling, if any, for the Covered Product (e.g., FDAapproved package insert and, if the response is for a consumer, FDA-approved
patient Labeling);

(b)

a prominent statement notifying the recipient that the FDA has not approved or
cleared the Covered Product as safe and effective for the Off-Label use addressed
in the accompanying materials;

(c)

a prominent statement disclosing the uses for which FDA has approved or cleared
the Covered Product; and

(d)

a report containing the results of a reasonable literature search using terms from
the request.
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5.19

BIPI Sales and BIPI Marketing may respond orally to an Unsolicited Request for

Off-Label information regarding a Covered Product only by offering to refer the request to BIPI
Medical, or by offering to put the HCP in touch with BIPI Medical.
Reprints Containing Off-Label Information
5.20

BIPI shall not disseminate information describing any Off-Label or unapproved

use of a Covered Product, unless such information and materials comply with the standards in
applicable FDA regulations and with recommendations in FDA Guidances for Industry,
including FDA’s “Guidance for Industry: Responding to Unsolicited Requests for Off-Label
Information About Prescription Drugs and Medical Devices” and FDA’s “Guidance for Industry:
Distributing Scientific and Medical Publications on Unapproved New Uses - Recommended
Practices,” or as revised,
5.21

BIPI Medical shall be responsible for the identification, selection, approval and

dissemination of Reprints Containing Off-Label Information regarding a Covered Product.
5.22

Reprints Containing Off-Label Information regarding a Covered Product:

(a)

shall be accompanied by the FDA approved Labeling for the Covered Product o r.
a prominently displayed and Clearly and Conspicuously described hyperlink that
will provide the reader with such information;

(b)

shall contain a Clear and Conspicuous disclosure in a prominent location, which
would include the first page or as a cover page where practicable, indicating that
the article discusses Off-Label information; and

(c)

shall not be referred to or used in a Promotional manner.

5.23

Reprints Containing Off-Label Information regarding a Covered Product may

only be disseminated if approved by BIPI Medical to HCPs.

11

i
5.24

i

This section of the Judgment does not apply to reprints containing only incidental

references to Off-Label information. If reprints have an incidental reference to Off-Label
information, such reprints shall contain the disclosures required by Paragraphs 5.22(a) and
5.22(b) in a prominent location, as defined above, and such incidental reference to Off-Label
information shall not be referred to or used in a Promotional manner as prohibited by Paragraph
5.22(c).
6. PAYMENT
6.1

No later than 30 days after the Effective Date of this Judgment, BIPI shall pay a

total amount of Thirteen Million Five Hundred Thousand Dollars ($13,500,000) to be divided
and paid by BIPI directly to each Signatory Attorney General of the Multistate Working Group
in an amount to be designated by, and in the sole discretion of, the Multistate Executive
Committee. Said payment shall be used by the States as attorneys’ fees and other costs of
investigation and litigation, or to be placed in, or applied to, the consumer protection
enforcement fund, including future consumer protection enforcement, consumer education,
litigation or local consumer aid fund or revolving fund, used to deft ay the costs of the inquiry
leading hereto, or any lawful purpose, at the sole discretion of each Signatory Attorney General.
The parties acknowledge that the payment described herein is not a fine, penalty, or payment in
lieu thereof.
7. RELEASE
7.1

By its execution of this Judgment, the State of Maine releases BIPI and all of its

past and present subsidiaries, predecessors, successors, assigns, parents, affiliates, each of their
current and former officers, directors, shareholders, employees, agents, contractors, and attorneys
(collectively, the “Released Parties”) from the following: all civil claims, parens patriae claims,
causes of action, damages, restitution, fines, attorney’s fees, costs, and penalties that the Maine
12

Attorney General has asserted or could have asserted against the Released Parties under the
above-cited consumer protection statutes or any common law claims concerning unfair,
fraudulent, or deceptive trade practices other than those described in Paragraph 7.2 resulting
Rom the Covered Conduct up to and including the Effective Date.
7.2

Notwithstanding any term of this Judgment, specifically reserved and excluded

from the release in Paragraph 7.1 as to any entity or person, including Released Parties, are any
and all of the following:
(a)

any criminal liability that any person and/or entity, including Released Parties,
has or may have to the State of Maine.

(b)

any civil or administrative liability that any person and/or entity, including
Released Parties, has or may have to the State of Maine not expressly
covered by the release in Paragraph 7.1 above, including, but not limited to, any
and all of the following claims:
(i)

state or federal antitrust violations;

(ii)

claims involving “best price,” “average wholesale price,” “wholesale
acquisition cost,” or any price-reporting practices;

(iii)

Medicaid claims including, but not limited to, federal Medicaid drug
rebate statute violations, Medicaid fraud or abuse, and/or kickback
violations related to any State’s Medicaid program;

(iv)

state false claims violations; and

(v)

actions of state program payors of the State of Maine arising Rom the
purchase of a Covered Product, except for the release of civil penalties
under the Maine Unfair Trade Practices Act.
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(c)

any claims individual consumers have or may have under the State of Maine’s
above-cited consumer protection law, and any common law claims individual
consumers may have concerning unfair, fraudulent or deceptive trade practices,
against any person and/or entity, including Released Parties.
8. DISPUTE RESOLUTION

8.1

For the purposes of resolving disputes with respect to compliance with this

Judgment, should any of the Signatory Attorneys General have a reasonable basis to believe that
BIPI has engaged in a practice that violates a provision of this Judgment subsequent to the
Effective Date of this Judgment, then such Attorney General shall notify BIPI in writing of the
specific objection, identify with particularity the provision of this Judgment that the practice
appears to violate, and give BIPI 30 days to respond to the notification; provided, however, that a
Signatory Attorney General may take any action if the Signatory Attorney General concludes
that, because of the specific practice, a threat to the health or safety of the public requires
immediate action. Upon receipt of written notice, BIPI shall provide a good-faith written
response to the Attorney General notification, containing either a statement explaining why BIPI
believes it is in compliance with the Judgment, or a detailed explanation of how the alleged
violation occurred and a statement explaining how BIPI intends to remedy the alleged breach.
Nothing in this section shall be interpreted to limit the state’s or Attorney General’s Civil
Investigative Demand (“CID”) or investigative subpoena authority, to the extent such authority
exists under applicable law, and BIPI reserves all of its rights in responding to a CID or
investigative subpoena issued pursuant to such authority.
8.2

Upon giving BIPI 30 days to respond to the notification described above, the

Signatory Attorney General shall also be permitted reasonable access to inspect and copy
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relevant, non-privileged, non-work product records and documents in the possession, custody, or
control of BIPI that relate to BIPI’s compliance with each provision of this Judgment pursuant to
that State’s CID or investigative subpoena authority. If the Signatory Attorney General makes or
requests copies of any documents during the course of that inspection, the Signatory Attorney
General will provide a list of those documents to BIPI.
8.3

The Signatory Attorney General may assert any claim that BIPI has violated this

Judgment in a separate civil action to enforce compliance with this Judgment, or may seek any
other relief afforded by law, but only after providing BIPI an opportunity to respond to the
notification described in Paragraph 8.1 above; provided, however, that the Signatory Attorney
General may take any action if the Signatory Attorney General concludes that, because of the
specific practice, a threat to the health or safety of the public requires immediate action.
9. GENERAL PROVISIONS
9.1

BIPI shall not cause third parties, acting on its behalf, to engage in practices from

which BIPI is prohibited by this Judgment.
9.2

This Judgment does not constitute an approval by any of the Signatory Attorneys

General of BIPPs business practices, and BIPI shall make no representation or claim to the
contrary.
9.3

Any failure by any party to this Judgment to insist upon the strict performance by

any other party of any of the provisions of this Judgment shall not be deemed a waiver of any of
the provisions of this Judgment, and such party, notwithstanding such failure, shall have the right
thereafter to insist upon the specific performance of any and all of the provisions of this
Judgment. This Judgment represents the full and complete terms of the settlement entered into
by the parties hereto. In any action undertaken by the parties, no prior versions of this Judgment,
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and no prior versions of any of its terms that were not entered by the Court in this Judgment, may
be introduced for any purpose whatsoever.
9.4

This Court retains jurisdiction of this Judgment and the parties hereto for the

purpose of enforcing and modifying this Judgment and for the puipose of granting such
additional relief as may be necessary and appropriate.
9.5

This Judgment may be executed in counterparts, and a facsimile or .pdf signature

shall be deemed to be, and shall have the same force and effect as, an original signature.
9.6

To the extent that any provision of this Judgment obligates BIPI to change any

policy(ies) or procedure(s) and to the extent not already accomplished, BIPI shall implement the
policy(ies) or procedure(s) as soon as reasonably practicable, but no later than 90 days after the
Effective Date of this Judgment.
9.7

The parties agree that neither of them shall be deemed the drafter of this Judgment

and that, in construing this Judgment, no provision hereof shall be construed in favor of one
party on the ground that such provision was drafted by the other.
9.8

All notices under this Judgment shall be provided to the following via email and

Overnight Mail:
For the State of Maine:
Linda J. Conti, Chief
Consumer Protection Division
Office of the Maine Attorney General
Burton Cross Office Building, 6th Floor
111 Sewall Street
Augusta, ME 04330
linda.conti@maine.gov
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For Boehringer Ingelheim Pharmaceuticals, Inc.:
Wick Sollers
King Sc Spalding LLP
1700 Pennsylvania Avenue, N.W.
Washington, DC 20006

JOINTLY APPROVED AND SUBMITTED FOR ENTRY BY:

Plaintiff State of Maine:
JANET T. MILLS
ATTORNEY GENERAL

Date:

I Z Z& i'Ÿ
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/
Carolyn A. Silsby, Maine Bar No. 3 0
Linda J. Conti, Maine Bar No. 3638
Assistant Attorneys General
Office of the Maine Attorney General
6 State House Station
Augusta, ME 04333-0006
(207) 626-8829
Y

17

i — -i

FOR BOEHRINGER INGELHEIM PHARMACEUTICALS, INC.

Date: December 19, 2017
HarolirJ. Friedman, Maine Bar No, 1252
Stephen B. Segal, Maine Bar. No. 5422
Verrill Dana LLP
One Portland Square
P.O.Box 586
Portland, ME 04112-0586
207-774-4000

FOR BOEHRINGER INGELHEIM PHARMACEUTICALS, INC.

Date:
Mark Jensen, Esq.
Brandt A. Leibe. Esq.
Daniel C. Sale, Esq.
King & Spalding LLP
Counselfo r Boehringer Ingelheim Pharmaceuticals, Inc.

1

FOR BOEHRINGER INGELHEIM PHARMACEUTICALS, INC.

Date:

By:
Christian Orth
Senior Vice President and Chief Financial Officer
Boehringer Ingelheim Pharmaceuticals, Inc.
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